Tormentil: The One Herb Researchers Actually Put to the Test

Almost every traditional herbal astringent shares the same fate: centuries of use, but never tested on people. Tormentil is one of the rare exceptions – and what that study found surprised even experts.

Why an unassuming meadow plant carries a blood-red name

Anyone who stumbles across tormentil (Potentilla erecta) on a nutrient-poor meadow would not guess there is anything special about it. The perennial rarely grows taller than 30 centimetres, and its yellow flowers stand out for having four petals instead of the five typical of the rose family. The name only reveals its secret on closer inspection: cut into the knobbly rhizome, and the exposed surface turns dark red within minutes. This is caused by oxidation of the tannins it contains on contact with air – a visual effect that had already secured the plant a place in folk medicine by the Middle Ages.

In 2024, the interdisciplinary Studienkreis Entwicklungsgeschichte der Arzneipflanzenkunde named tormentil Medicinal Plant of the Year – not because of any spectacular new proof of efficacy, but because it exemplifies a group of plants that research long neglected: tannin-rich herbal drugs.

The Latin name "tormentil" hints at the plant's earlier role: it derives either from "tormentum" (pain, torment) or from "tormina" (abdominal cramps, dysentery) – a clear sign of what the rhizome was used for over the centuries. Hildegard of Bingen already recommended tormentil in her natural history in the mid-12th century, among other things against fever. In the Middle Ages, its reputation even extended to hopes of protection against the plague – an expectation the plant naturally could not live up to. What remained was the far more modest, but better-supported role as an astringent for diarrhoea and sore oral mucosa.

What makes the rhizome so chemically concentrated

Hardly any native plant reaches as high a tannin content as Potentilla erecta: the dried rhizome contains 15 to 22 percent tannins, predominantly condensed catechin tannins (proanthocyanidins), along with a smaller share of hydrolysable ellagitannins, chiefly agrimoniin. Flavonoids, triterpene saponins, and phenolic acids round out the profile. This group of compounds explains the astringent, tissue-contracting effect: tannins bind to proteins on the mucosal surface and form a kind of protective layer there – a mechanism well studied through leather tanning and transferable to skin and mucous membranes.

The rhizome is preferably harvested in spring, shortly before flowering, when tannin content peaks. Dried material loses potency over time and should not be stored longer than a year.

The study that sets tormentil apart from most herbs

The vast majority of traditional astringent plants have never been tested in a controlled human trial – their use rests on tradition and laboratory chemistry alone. Tormentil is an exception here, and one backed by concrete numbers.

At the Children's Hospital for Infectious Diseases No. 3 in St Petersburg, Subbotina and colleagues conducted a randomised, double-blind, placebo-controlled trial in 2003 involving 40 children aged three months to seven years with laboratory-confirmed rotavirus diarrhoea. One group received tormentil root extract drops, the other a visually identical placebo. The result: median diarrhoea duration was three days in the extract group versus five days in the placebo group (p < 0.0001). Forty-eight hours after admission, 40 percent of treated children were free of diarrhoea, compared with substantially fewer in the placebo group. Rehydration needs were also lower in the treatment group.

For such a small, unspecific medicinal plant, that is a remarkably clean study design – randomised, double-blind, placebo-controlled, with a clearly defined, laboratory-confirmed condition. It is exactly what makes tormentil a special case among European tannin-rich herbal drugs.

What the research on ulcerative colitis has found – and where it hits its limits

The second major human study on tormentil moves into very different territory: the chronic inflammatory bowel disease ulcerative colitis. A team led by Huber at University Hospital Freiburg tested a tormentil root extract in 16 adult patients with active disease in 2007, using four escalating daily doses – 1200, 1800, 2400, and 3000 milligrams – each held for three weeks with four-week washout phases in between.

At the 2400-milligram dose, both the clinical activity index and the inflammation marker CRP improved markedly at the median. Six of the 16 participants (38 percent) reported mild upper abdominal discomfort, though this never led to discontinuation.

The crucial catch lies in the design: this study was open-label, meaning no placebo group and no blinding. That does not mean the observed effects are imaginary – but it does mean a systematic bias from expectation or the natural course of the disease cannot be ruled out. A team of authors framed the situation in a 2025 journal article this way: tormentil exemplifies a gap between what is empirically observed in practice and what formal approval procedures require as evidence. To this day, the placebo-controlled confirmatory trial that would turn a promising open-label signal into solid proof of efficacy for the colitis indication is still missing.

What a brand-new laboratory study reveals about tormentil and the immune system

In November 2025, a team from the Medical University of Warsaw published a paper addressing a previously unexplored angle on tormentil: what actually happens once the tannins reach the gut? Earlier research mostly examined the plant extract itself – this study additionally tested the breakdown products that form when the human gut microbiota metabolises tormentil's polyphenols further.

In a cell model using human neutrophil granulocytes and THP-1-derived macrophages, both the extract itself and several of its microbial breakdown products significantly reduced the production of reactive oxygen species. Certain fractions also reduced the release of the pro-inflammatory messengers IL-1β and TNF-α, while interleukin-8 paradoxically increased – a sign that tormentil does not simply "dampen" the immune system but selectively modulates specific signalling pathways. The fractions richest in catechins and triterpenoid compounds proved the most active.

These findings come from a cell model, not from people – so they cannot be translated directly into a practical recommendation. But they offer, for the first time, a mechanistic explanation for why a tannin-rich herbal drug that is barely absorbed in the gut could produce systemic anti-inflammatory effects at all: it is not the original substance itself that acts, but what gut bacteria turn it into.

How Europe's medicines agency classifies tormentil

The European Medicines Agency (EMA), through its Committee on Herbal Medicinal Products (HMPC), classifies tormentil root as a traditional herbal medicinal product – meaning long-standing use is considered sufficiently documented without requiring modern clinical trials in full. Two traditional indications are recognised: mild, unspecific diarrhoea, and mild inflammation of the oral and pharyngeal mucosa, applied externally as a rinse or gargle.

Notably, the rotavirus trial in children, despite its clean design, has not changed this traditional classification – partly because a single study rarely suffices, regulatorily, for a jump to "well-established use," and partly because the EMA explicitly recommends the traditional use only for adults. For the same reason, it advises against use in pregnancy and breastfeeding: for these groups, the data simply remain too sparse.

Safety and use

Overall, the published safety data on tormentil look favourable. An animal study on acute toxicity found no signs of organ damage or behavioural abnormalities even at very high doses and classified aqueous rhizome extracts as safe. This aligns with the side-effect profile seen in the two human trials: in the colitis study, just over a third of participants experienced mild upper abdominal discomfort, while the paediatric rotavirus trial reported no relevant adverse effects.

• Children: The placebo-controlled trial was specifically conducted in children; nevertheless, for regulatory reasons the EMA recommends the traditional use generally only for adults. Use in children belongs in a doctor's hands.
• Pregnancy and breastfeeding: Not recommended by the EMA due to insufficient data.
• Side effects: Occasional mild gastrointestinal discomfort possible at higher doses.
• Interactions: As a tannin-rich herbal drug, tormentil could theoretically reduce the gut absorption of certain medications and minerals if taken at the same time – leaving a one- to two-hour gap is the usual precaution for tannin-rich plant preparations.

Conclusion: a tannin-rich herbal drug with a rare proof point and open chapters

Tormentil is among the few traditional medicinal plants for which a randomised, placebo-controlled human trial actually exists – and for the indication studied, acute rotavirus diarrhoea in children, it came out clearly positive. For the second major application, ulcerative colitis, only an open-label, dose-escalating study without a control group is available so far: a promising but methodologically still unconfirmed signal. A brand-new laboratory study from November 2025 now offers the first mechanistic clues as to how tormentil's tannins might act on the immune system by way of the gut microbiota – basic research showing that this "forgotten" medicinal plant is far from fully explored.